Hayden E. Klein

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.

Research found that maternal loss of a partner or older child, as well as the loss of a close relative due to unnatural causes in the year before or during pregnancy, were linked to a heightened risk of heart failure in offspring.

A survey of more than 1500 people revealed misconceptions about living with diabetes, particularly regarding the efficacy of GLP-1 weight loss drugs as a standalone solution for managing their health goals.

Starting summer 2024, individuals across the US will be able to purchase a continuous glucose monitor (CGM) without needing a prescription.

Interviews with Katherine Meese, PhD, of University of Alabama at Birmingham, and Nadine Barrett, PhD, MS, MPH, of Wake Forest University, from day 2 of the Association of Cancer Care Centers 50th Annual Meeting & Cancer Center Business Summit (ACCC AMCCBS).

Stephen Speicher, MD, Flatiron Health, highlights the organization's frameworks for ensuring ethical artificial intelligence (AI) usage, emphasizing the importance of providers and health systems asking critical questions when considering AI tools.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, talks about tailoring the Stanford Model of Professional Fulfillment to support the postpandemic oncology workforce.

Interviews with Kirollos Hanna, PharmD, BCPS, BCOP, of Minnesota Oncology and Mayo Clinic College of Medicine, and Alti Rahman, MHA, MBA, of American Oncology Network, from day 1 of the Association of Cancer Care Centers 50th Annual Meeting & Cancer Center Business Summit (ACCC AMCCBS).

Leslie Busby, MD, chairman of the US Oncology Network Pharmacy & Therapeutics Committee, discusses the process of developing patient-centered care plans within the framework of an accountable care organization (ACO) and the importance of staying up to date with the latest best practices and therapies.

According to the authors, these improvements may be part of the reason why there was a lower rate of major adverse cardiovascular events in the REPRIEVE study.

This study was the first of its kind to explore how taking statin medication affects blood vessel function and exercise response in patients with heart failure with preserved ejection fraction (HFpEF), although the cohort only included 16 patients.

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Increased daily step count was linked to reduced risks of overall heart failure (HF) and HF with preserved or reduced ejection fraction.

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.

Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.

Although the prevalence of myocardial infarction (MI) was doubled among men compared with women with homozygous familial hypercholesterolemia (HoFH), both sexes had similar ages at first MI.

From an interview conducted during Patient-Centered Oncology Care 2023.

From an interview conducted during Patient-Centered Oncology Care 2023.

From an interview conducted during Patient-Centered Oncology Care 2023.

From an interview conducted during Patient-Centered Oncology Care 2023.

Participants in the Risk Assessment and Management Program-Diabetes Mellitus had reduced risks of developing all-cause dementia by 28%, Alzheimer disease by 15%, vascular dementia by 39%, and other or unspecified dementia by 29%.

Patients enrolled in a preventive drug list (PDL) benefit saw an 8.4% reduction in acute, preventable diabetes complication days, and PDL members residing in lower-income areas saw a 10.2% decrease compared with control members.

Experts explain how diabetes is diagnosed during pregnancy, how treatment differs from that of nonpregnant individuals, the importance of diabetes technology education, and how things change postpartum.

Amazon and Health Warehouse’s direct-to-consumer pharmacies had the most expensive and commonly used generic drugs available in 2020, whereas Walmart only had a small fraction.

Light-to-moderate alcohol consumption seemed to provide greater protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status (SES) compared with those with lower SES, likely due to gaps in access to necessary care.

Among Medicare beneficiaries, implantation was especially frequent for female patients and those undergoing tricuspid valve replacement with or without concomitant left-sided heart surgeries.

Natasha Halasa, MD, MPH, of Vanderbilt University Medical Center (VUMC), discusses the active population-based surveillance that the New Vaccine Surveillance Network conducts.

Natasha Halasa, MD, MPH, Vanderbilt University Medical Center, discusses her role as principal investigator of the Vanderbilt site of the New Vaccine Surveillance Network.

UnitedHealthcare is incorporating real-world evidence into pathways design and policy formulation, leveraging its members' data to evaluate the impact of different regimens on health resource utilization and costs, explains Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare.

Drug prices in the US increased 4.4% annually and median out-of-pocket (OOP) costs increased 9.6% annually from 2009 to 2018, but there was no direct link between these amounts for individual drugs.